A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Alcobra Ltd.
Sponsor:
Information provided by (Responsible Party):
Alcobra Ltd.
ClinicalTrials.gov Identifier:
NCT02126995
First received: April 29, 2014
Last updated: July 10, 2014
Last verified: April 2014
  Purpose

This study is a multisite, randomized, double-blind, placebo-controlled, phase 2 study of MG01CI (low dose and high dose once daily) for 6 weeks compared with placebo in a 1:1 ratio of 60 adolescent and adult subjects with Fragile X Syndrome (FXS). Following Screening, subjects will be randomized to MG01CI or matching placebo at Baseline (Day 0) and the 6 week Double-blind Treatment Period will begin on Day 1.

The first 4 weeks of the treatment period will be a dose-optimization period,

All subjects will start with a single daily tablet of either low dose of metadoxine or matching blinded placebo. At weekly visits/phone assessments, the investigator will evaluate the dose based upon the investigator's assessment of safety and tolerability. If the subject demonstrates safety or tolerability concerns with the low dose after 1 or 2 weeks of treatment, then the subject will be discontinued. If there are no concerns about safety and tolerability after 2 weeks of treatment, then the dose will be increased to high dose or placebo. If at the high dose there are concerns about safety and tolerability, then the dose will be either kept the same or reduced to low dose for the remainder of the treatment period.

There will be a 2-week Follow-up Period after the last dose of study treatment or early termination.


Condition Intervention Phase
Fragile X Syndrome
Drug: MG01CI extended-release tablet
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A 6-week, Randomized, Multicenter, Double-blind, Parallel, Flexed and Fixed-dose Study of MG01CI (Metadoxine Extended-release) Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

Resource links provided by NLM:


Further study details as provided by Alcobra Ltd.:

Primary Outcome Measures:
  • Evaluation of efficacy of MG01CI by Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale (ADHD RS-IV) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    To evaluate the efficacy of MG01CI (Metadoxine Extended-release) once daily compared with placebo in the treatment of symptoms of FXS in adults and adolescents as measured by the inattentive subscale of the Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale (ADHD RS-IV) (as rated by the investigator in a clinical interview of the parent/legal authorized guardian/consistent caregiver).


Secondary Outcome Measures:
  • Evaluation of efficacy of MG01C as measured by total score on the ADHD RS-IV. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    To evaluate the efficacy of MG01CI (Metadoxine Extended-release) once daily compared with placebo in the treatment of symptoms of FXS in adults and adolescents as measured by the total score on the ADHD RS-IV.


Other Outcome Measures:
  • Evaluation of safety by AE's count [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
    To evaluate the safety, and tolerability of treatment with MG01CI once daily on the adverse events (AEs);

  • Evaluation of safety by AE's vital sign measurements [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
  • Safety evaluation by lab tests (hematology, chemistry, and urinalysis) [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
  • Evaluation of safety by physical and neurological examinations [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: June 2014
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metadoxine Immediate/Slow-release
low dose or high dose administered orally once daily
Drug: MG01CI extended-release tablet
Other Name: Metadoxine (pyridoxol L-2-pyrrolidone-5-carboxylate)
Placebo Comparator: Placebo
Placebo tablet identical in appearance to study investigational product Administered orally once daily

Detailed Description:

This study is a multisite, randomized, double-blind, placebo-controlled, phase 2 study of MG01CI (low and high doses of metadoxine once daily) for 6 weeks compared with placebo in a 1:1 ratio of 60 adolescent and adult subjects with FXS. Following Screening, subjects will be randomized to MG01CI or matching placebo at Baseline (Day 0) and the 6 week Double-blind Treatment Period will begin on Day 1.

The first 4 weeks of the treatment period will be a dose-optimization period, during which the subject's dose of MG01CI or placebo will be optimized. Investigators and subjects will be blinded with regard to whether the subject is taking active drug or placebo; however, subjects taking low dose active or placebo will take only 1 tablet per day, while those taking high dose active or placebo will take 2 tablets per day. A phone follow-up assessment of safety, tolerability, and Clinical Global Impression of Improvement (CGI-I) will occur during titration after 1 and 3 weeks of treatment; if the investigator has any significant concerns regarding safety and tolerability, the subject will be assessed at the site at an unscheduled visit. All subjects will be assessed at the site after 2 weeks and 4 weeks of treatment.

All subjects will start with a single daily tablet of either low dose or matching blinded placebo. At weekly visits/phone assessments, the investigator will evaluate the dose based upon the investigator's assessment of safety and tolerability. If the subject demonstrates safety or tolerability concerns with the low dose after 1 or 2 weeks of treatment, then the subject will be discontinued. If there are no concerns about safety and tolerability after 2 weeks of treatment, then the dose will be increased to 2 tablets of either high dose of active treatment or placebo. If at high dose there are concerns about safety and tolerability, then the dose will be either kept the same or reduced tolow dose for the remainder of the treatment period.

The last 2 weeks of the treatment period will be a dose-maintenance period. During the dose-maintenance period, the subject will maintain his or her optimal dose as determined at the end of the dose-optimization period. A phone follow-up assessment of safety, tolerability, and CGI-I will occur after 5 weeks of treatment (after 1 week of dose maintenance). If the investigator has any significant concerns regarding safety and tolerability, the subject will be assessed at the site at an unscheduled visit. The subject will be assessed at the site after 6 weeks of treatment (after 2 weeks of dose maintenance).

There will be a 2-week Follow-up Period after the last dose of study treatment or early termination.

  Eligibility

Ages Eligible for Study:   15 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is a man or a non-pregnant, non-lactating woman aged 15 to 55 years, inclusive, at the Screening Visit.
  2. Subject has Fragile X Syndrome with a molecular genetic confirmation of the full Fragile X Mental Retardation (FMR1) mutation (≥200 CGG repetitions).
  3. Subject has a score of 12 or greater on the inattentive subscale of the ADHD RS IV (as rated by the investigator in a clinical interview of the parent/legal authorized guardian/consistent caregiver).
  4. Current treatment with no more than 3 prescribed psychotropic medications. Anti epileptic medications are permitted and are not counted as psychotropic medications if they are used for treatment of seizures. Anti-epileptics for other indications, such as the treatment of mood disorders, count towards the limit of permitted medications.

    1. Permitted concomitant psychotropic medications (except anti-epileptic medications and stimulants; see 4b and 4d) must be at a stable dose and dosing regimen for at least 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication.
    2. Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication.
    3. Subjects with a history of seizure disorder who are currently receiving treatment with anti-epileptics must have been seizure-free for 3 months preceding Screening, or must be seizure-free for 3 years if not currently receiving anti-epileptics.
    4. Stimulant medications must be at a stable dose and dosing regimen for 12 weeks prior to Screening and must remain stable during the period between Screening and the end of the treatment period (Week 6/early termination).
  5. Behavioral treatments (excluding psychotherapy; see exclusion criteria) must be stable for 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication.
  6. Subject has a parent, legal authorized guardian or consistent caregiver who interacts with the subject for at least 10 hours per week and is able to provide weekly rating forms of the subject's behavior.
  7. Female subjects of childbearing potential must agree to use an effective contraceptive throughout the study (eg, oral contraceptives or Norplant®; a reliable double barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam]; intrauterine devices; partner with vasectomy; or abstinence) and for at least a month after the study, and must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit. Females of childbearing potential are defined as women who are between menarche and 2 years post-menopause and who are not surgically sterilized. Female subjects who are not sexually active, and who agree to be abstinent throughout the study, will not be required to use birth control.
  8. Subject and caregiver are able to attend the clinic regularly and reliably.
  9. Subject is able to swallow tablets and capsules.
  10. For subjects who are not their own legal guardian, subject's parent/legal authorized guardian is able to understand, read, write, and speak English fluently to complete the study-related materials (or Hebrew for Israeli subjects).
  11. For subjects who are not their own legal guardian, subject's parent/legal authorized guardian is able to understand and sign an informed consent form to participate in the study.
  12. If subject is his/her own legal guardian, he/she can understand and sign informed consent to participate in the study.
  13. If subject is not their own legal guardian, the subject provides assent for participation in the study, if the subject has the cognitive ability to provide assent

Exclusion Criteria:

  1. Treatment within the 2 weeks prior to Screening with monoamine oxidase (MAO) inhibitors, lithium, acamprosate, racemic baclofen, investigational metabotropic glutamate receptor subtype 5 (mGluR5) medications, d-cycloserine, oxytocin, carbetocin, tricyclic antidepressants, modafinil, armodafinil, benzodiazepines (unless used for seizure control), memantine, amantadine, bupropion, lovastatin, l dopa, cisplatin, or simvastatin.
  2. Current treatment with an N-methyl-D-aspartate (NMDA) antagonist.
  3. Subject is planning to commence psychotherapy or cognitive behavior therapy (CBT) during the period of the study or had begun psychotherapy or CBT within 6 weeks prior to Screening.
  4. History of or current cardiovascular, renal, hepatic, respiratory, or gastrointestinal disease that may interfere with the absorption, distribution, metabolism, or excretion of the study medication, or that may interfere with the interpretation of the safety, tolerability, or efficacy of the study medication.
  5. History of or current cerebrovascular disease or clinically significant brain trauma.
  6. Current major depressive disorder (subject must be free of the most recent episode for 3 months prior to randomization).
  7. History of a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)-defined substance use disorder in the 3 months prior to Screening.
  8. Clinically significant abnormalities, in the investigator's judgment, in safety laboratory tests, vital signs, or ECG, as measured at Screening.
  9. Significant hearing or visual impairment that may affect the subject's ability to complete the test procedures.
  10. Enrollment in another clinical trial within the 30 days preceding Screening.
  11. Any psychiatric condition (eg, schizophrenia or personality disorder as diagnosed by DSM-IV) or clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation as determined by the investigator using medical history, physical examination, neurological examination, laboratory tests, and electrocardiograms. Common diseases such as mild hypertension, well-controlled type 2 diabetes mellitus (hemoglobin A1C [Hgb A1C] <6.5%), etc. are allowed per the investigator's judgment as long as they are stable and controlled by medical therapy that is constant for at least 8 weeks before randomization and subsequently throughout the study. If there are any concerns about the suitability of the subject's medical or surgical condition, the investigator should review the subject's history with the medical monitor. Subjects with autism spectrum disorder or anxiety disorder will be allowed.
  12. Subject has known or suspected human immune deficiency virus-positive status or has diseases such as acquired immunodeficiency disorder, hepatitis C, hepatitis B, or tuberculosis.
  13. Subject has a history of an allergy or sensitivity to B-complex vitamins.
  14. Subject has used mega-dose vitamin B6/pyridoxine during the 28 days before the Screening Visit. Routine multivitamin supplements will be allowed.
  15. Subject has used high-dose supplements of omega-3 fatty acids ≥ 500 mg (such as softgels, capsules, or fish oils; regular daily dietary consumption of fish is allowed) or folic acid supplements (other than routine multivitamin supplements) at any time during the 2 weeks before the Screening Visit.
  16. Subject is related to the sponsor, investigator, or study staff.
  17. Subject has any condition that, in the principal investigator's opinion, would place the subject at risk or influence the conduct of the study or interpretation of results.
  18. Subject is pregnant, lactating, or using an inadequate contraceptive method. -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02126995

Contacts
Contact: Jonathan Rubin, MD Debbie@alcobra-pharma.com
Contact: Aviva Galili Taiber, M. Sc aviva@alcobra-pharma.com

Locations
United States, Arizona
Southwest Autism Research & Resource Center Recruiting
Phoenix,, Arizona, United States
United States, California
UC Davis MIND Institute Not yet recruiting
Sacramento,, California, United States
United States, Colorado
University of Colorado Children's Hospital Not yet recruiting
Aurora,, Colorado, United States
United States, Georgia
Emory University School of Medicine Not yet recruiting
Decatur,, Georgia, United States
United States, Illinois
RUSH Recruiting
Chicago,, Illinois, United States
United States, Maryland
Kennedy Krieger Institute Not yet recruiting
Baltimore,, Maryland, United States
United States, Massachusetts
University of Massachusetts Not yet recruiting
Worcester,, Massachusetts, United States
United States, Ohio
Cincinnati Children's Hospital Not yet recruiting
Cincinnati,, Ohio, United States
United States, Pennsylvania
Suburban Research Associates Recruiting
Media,, Pennsylvania, United States
United States, Texas
Baylor / Texas Children's Hospital Not yet recruiting
Houston,, Texas, United States
United States, Washington
Univ. of Washington/Seattle Children's Hospital Not yet recruiting
Seattle,, Washington, United States
Principal Investigator: Stein, MD         
Israel
Sheba Academic Medical Center Not yet recruiting
Ramat Gan, Israel
Sponsors and Collaborators
Alcobra Ltd.
Investigators
Principal Investigator: Elizabeth Berry-Kravis, MD, PhD Rush University Medical Center
  More Information

No publications provided

Responsible Party: Alcobra Ltd.
ClinicalTrials.gov Identifier: NCT02126995     History of Changes
Other Study ID Numbers: AL014
Study First Received: April 29, 2014
Last Updated: July 10, 2014
Health Authority: United States: Food and Drug Administration
Israel: Ministry of Health

Keywords provided by Alcobra Ltd.:
Fragile X Syndrome, Fra(X) Syndrome, FRAXA Syndrome

Additional relevant MeSH terms:
Fragile X Syndrome
Mental Retardation, X-Linked
Genetic Diseases, X-Linked
Syndrome
Disease
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Sex Chromosome Disorders
Chromosome Disorders
Congenital Abnormalities
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Metadoxine
Alcohol Deterrents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 18, 2014